Ontology highlight
ABSTRACT: Significance
Although clear progress has been made in expanding the availability of precision oncology-based treatment paradigms, our results suggest a continued unmet need for innovative therapeutic strategies, particularly for cancers with currently undruggable oncogenic drivers. See related commentary by Horak and Fröhling, p. 18. This article is featured in Selected Articles from This Issue, p. 5.
SUBMITTER: Suehnholz SP
PROVIDER: S-EPMC10784742 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature
Suehnholz Sarah P SP Nissan Moriah H MH Zhang Hongxin H Kundra Ritika R Nandakumar Subhiksha S Lu Calvin C Carrero Stephanie S Dhaneshwar Amanda A Fernandez Nicole N Xu Benjamin W BW Arcila Maria E ME Zehir Ahmet A Syed Aijazuddin A Brannon A Rose AR Rudolph Julia E JE Paraiso Eder E Sabbatini Paul J PJ Levine Ross L RL Dogan Ahmet A Gao Jianjiong J Ladanyi Marc M Drilon Alexander A Berger Michael F MF Solit David B DB Schultz Nikolaus N Chakravarty Debyani D
Cancer discovery 20240101 1
There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which molecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two temporally distinct versions of the OncoKB knowledge base deployed 5 years apart. Between 2017 and 2022, we observed an increase from 8.9% ...[more]